Psilocybin and the Brain: What Research Is Discovering Psilocybin has gone from fringe to well-funded inside fifteen years, and the volume of coverage has outrun the volume of solid findings. This is a short, deliberately unexcited summary of what is reasonably established, what is promising, and what has not held up.
The pharmacology, briefly Psilocybin is a prodrug: the body converts it to psilocin, which acts principally as an agonist at the serotonin 5-HT2A receptor. Blocking that receptor blocks the subjective effects almost completely, which is about as clean a mechanistic result as this field offers.
What imaging shows Reduced integrity of the default mode network during the acute phase — the finding behind most popular writing on the subject. Increased communication between regions that do not normally talk to each other much. Changes in cortical excitability that persist for some days beyond the acute effects. These are group-level results from small samples. They describe a direction, not a mechanism of benefit, and mapping them onto anything a person feels is still largely inference.
What the clinical trials show Trials in treatment-resistant depression have reported meaningful effect sizes, and a large phase 2b published in 2022 found a single 25 mg dose beat 1 mg at three weeks — with the difference narrowing by twelve. Results in end-of-life anxiety and in alcohol use disorder have also been encouraging. Every one of these was run with screening, preparation, a supervised session and structured follow-up.
The therapy in "psychedelic-assisted therapy" is not decoration. It is most of the protocol. The problems the field acknowledges Blinding barely works. Participants almost always know which arm they are in, and expectancy is a large uncontrolled variable. Samples skew small, young, healthy and self-selected for enthusiasm. Long-term durability is thinly evidenced; several effects shrink by six to twelve months. Adverse events in unsupervised settings are systematically under-recorded. Where Europe stands Psilocybin remains a controlled substance in Germany and across the EU, with trial access only. The Czech Republic passed legislation in 2025 opening medical access under specialist supervision, and Switzerland has run a limited compassionate-use programme since 2014. Nothing sold here is a medicine or offered as a treatment for anything.
